TipRanks
Advertisement
Advertisement

HK:2575 Stock Latest News

Xuanzhu Biopharmaceutical Flags Share Price Surge Amid Early-Stage Acquisition Talks
Company AnnouncementsXuanzhu Biopharmaceutical Flags Share Price Surge Amid Early-Stage Acquisition Talks
24d ago
2575
Xuanzhu Biopharma INEDs Report No Conflicts With Controlling Shareholders in 2025 Review
PremiumCompany Announcements
Xuanzhu Biopharma INEDs Report No Conflicts With Controlling Shareholders in 2025 Review
25d ago
2575
Xuanzhu Biopharma Strikes Thailand Commercial Deal for Breast Cancer Drug Bireociclib
PremiumCompany Announcements
Xuanzhu Biopharma Strikes Thailand Commercial Deal for Breast Cancer Drug Bireociclib
1M ago
2575
Xuanzhu Biopharmaceutical Narrows Interim Loss as Revenue Surges on New Products
PremiumCompany Announcements
Xuanzhu Biopharmaceutical Narrows Interim Loss as Revenue Surges on New Products
2M ago
2575
Xuanzhu Biopharmaceutical Sets Board Meeting to Approve 2026 Interim Results
PremiumCompany Announcements
Xuanzhu Biopharmaceutical Sets Board Meeting to Approve 2026 Interim Results
2M ago
2575
Xuanzhu Biopharm ordered to pay RMB9.33 million in arbitration over generic drug deal
PremiumCompany AnnouncementsXuanzhu Biopharm ordered to pay RMB9.33 million in arbitration over generic drug deal
3M ago
2575
Xuanzhu’s Anaprazole Wins NMPA Review Nod for Reflux Esophagitis
Premium
Company Announcements
Xuanzhu’s Anaprazole Wins NMPA Review Nod for Reflux Esophagitis
3M ago
2575
Xuanzhu Biopharma Advances Anaprazole into Phase III Trial for H. pylori Eradication
Premium
Company Announcements
Xuanzhu Biopharma Advances Anaprazole into Phase III Trial for H. pylori Eradication
4M ago
2575
Xuanzhu Biopharmaceutical Shareholders Approve AGM Resolutions and Governance Overhaul
PremiumCompany Announcements
Xuanzhu Biopharmaceutical Shareholders Approve AGM Resolutions and Governance Overhaul
4M ago
2575
Xuanzhu Biopharmaceutical Adds Employee Representative to Board as Executive Director Resigns
PremiumCompany Announcements
Xuanzhu Biopharmaceutical Adds Employee Representative to Board as Executive Director Resigns
4M ago
2575
Xuanzhu Biopharmaceutical updates board and committee roles
PremiumCompany Announcements
Xuanzhu Biopharmaceutical updates board and committee roles
4M ago
2575
Xuanzhu Biopharmaceutical Sets 2025 AGM With Governance and Capital Mandates on Agenda
PremiumCompany Announcements
Xuanzhu Biopharmaceutical Sets 2025 AGM With Governance and Capital Mandates on Agenda
5M ago
2575
Xuanzhu Biopharmaceutical Overhauls Governance Structure and Board Composition
PremiumCompany AnnouncementsXuanzhu Biopharmaceutical Overhauls Governance Structure and Board Composition
5M ago
2575
Xuanzhu Biopharmaceutical Completes Full H-Share Circulation on HKEX
Premium
Company Announcements
Xuanzhu Biopharmaceutical Completes Full H-Share Circulation on HKEX
5M ago
2575
Xuanzhu Biopharma Posts Encouraging Early Data for NG-350A in Rectal Cancer
Premium
Company Announcements
Xuanzhu Biopharma Posts Encouraging Early Data for NG-350A in Rectal Cancer
6M ago
2575
Xuanzhu’s ALK Inhibitor Dirozalkib Delivers Strong Phase III Results in First-Line Lung Cancer
PremiumCompany Announcements
Xuanzhu’s ALK Inhibitor Dirozalkib Delivers Strong Phase III Results in First-Line Lung Cancer
6M ago
2575
Xuanzhu Biopharmaceutical Wins Approval for Major H Share Full Circulation
PremiumCompany Announcements
Xuanzhu Biopharmaceutical Wins Approval for Major H Share Full Circulation
6M ago
2575
Xuanzhu Biopharm Wins Green Light for Phase III Anaprazole Trial in H. pylori
PremiumCompany Announcements
Xuanzhu Biopharm Wins Green Light for Phase III Anaprazole Trial in H. pylori
6M ago
2575
Xuanzhu Biopharmaceutical Wins CSRC Nod for H Share Full Circulation Plan
PremiumCompany Announcements
Xuanzhu Biopharmaceutical Wins CSRC Nod for H Share Full Circulation Plan
6M ago
2575
Xuanzhu Biopharm Licenses Key Cancer Drugs to Boston Oncology for MENA Expansion
PremiumCompany AnnouncementsXuanzhu Biopharm Licenses Key Cancer Drugs to Boston Oncology for MENA Expansion
6M ago
2575
Xuanzhu Biopharmaceutical Narrows Annual Loss on Surging Revenue and Deep Cost Cuts
Premium
Company Announcements
Xuanzhu Biopharmaceutical Narrows Annual Loss on Surging Revenue and Deep Cost Cuts
7M ago
2575
Xuanzhu’s Breast Cancer Drug Bireociclib Delivers Strong Phase 3 Results Published in JAMA Oncology
Premium
Company Announcements
Xuanzhu’s Breast Cancer Drug Bireociclib Delivers Strong Phase 3 Results Published in JAMA Oncology
7M ago
2575

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >